Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
What Are the U.S. Market Access Levers and Hurdles Facing Orally Administered, Small-Molecule Targeted Oncology Drugs for Renal Cell Carcinoma and Hepatocellular Carcinoma? | Physician & Payer Forum | US| 2015
A Survey of Medical Oncologists and Managed Care Organization Pharmacy and Medical Directors The hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) markets differ with respect to…